BDNF mimetics: GSB, GBK & GTSМиметики BDNF
Small synthetic peptides designed to mimic parts of brain-derived neurotrophic factor (BDNF), a protein involved in nerve-cell survival and signaling.
What the studies found
Animal research · 2016
Mimetics of brain-derived neurotrophic factor loops 1 and 4 are active in a model of ischemic stroke in rats
GSB-106 and GSB-214 reduced infarct volume by approximately 66% and 28%, respectively, in this experiment.
Study notes · methods, sources and limitations
Participants or model Rat middle cerebral artery occlusion plus HT-22 signaling assays
Important limitations
- Animal results do not establish benefit or comparative potency in people. Effects are compound-specific and cannot be assigned to all BDNF mimetics.
Drug design, development and therapy · PMID 27843294 · Indexed abstract
Animal research · 2023
LC-MS/MS determination of GTS-201, a dipeptide mimetic of the brain-derived neurotrophic factor, and neurotransmitter metabolites with application to a pharmacokinetic study in rats.
After intraperitoneal GTS-201 in rats, reported elimination half-lives were about 19.5 minutes in plasma and 87.5 minutes in brain. Relative brain tissue availability was 2.9%; this is not human oral bioavailability.
Study notes · methods, sources and limitations
Participants or model Rat pharmacokinetics; plasma and brain LC-MS/MS
Important limitations
- Preclinical findings do not establish human benefit or safety. Abstract only. Full methods and independent replication remain unconfirmed.
Journal of pharmaceutical and biomedical analysis · Indexed abstract
Animal research · 2022
Antidepressant-like Effects of BDNF and NGF Individual Loop Dipeptide Mimetics Depend on the Signal Transmission Patterns Associated with Trk
Study of multiple preparations
GSB-106 showed acute antidepressant-like activity; GSB-214 also became active with repeated administration. GTS-201 was inactive in this forced-swim comparison. Different signaling patterns did not yield interchangeable behavioral effects.
Study notes · methods, sources and limitations
Participants or model Rodent forced-swim tests; comparison with cell-signaling results
Important limitations
- Behavioral proxies are not a clinical diagnosis or treatment outcome. Different schedules and models limit cross-compound comparisons.
Primary source linked above · Publication record
About BDNF mimetics: GSB, GBK & GTS
Names in this research collection
GSB-104 · GSB-106 · GSB-120 · GSB-207 · GSB-214 · GBK-108 · GBK-201 · GTS-201 · TrkB
Research background
Small experimental mimetics of different BDNF loops, grouped for comparison of chemistry, signaling and behavioral results.
- Compound class
- Peptide research family
- Research collection
- Neuropeptide research · editorial grouping
- Institutions in linked studies
- See individual study records
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
No human treatment trial assessed for this family
Study methods
Member-specific studies; patents and archival leads identified separately
Independent replication
Independent replication not established by the records collected here
Source access
Primary abstracts, selected full texts, patents and explicit retrieval targets
Safety evidence
Cell and animal effects do not establish human safety; analogues may differ
Open a topic for the evidence assessment.
Patents and claimed inventions
These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Findings by study
Animal research · 2016
Mimetics of brain-derived neurotrophic factor loops 1 and 4 are active in a model of ischemic stroke in rats
GSB-106 and GSB-214 reduced infarct volume by approximately 66% and 28%, respectively, in this experiment.
Study notes and original source
Mimetics of brain-derived neurotrophic factor loops 1 and 4 are active in a model of ischemic stroke in rats
Gudasheva TA, Povarnina P, Logvinov IO, Antipova TA, Seredenin SB · Drug design, development and therapy · PMID 27843294
GSB-106 and GSB-214 reduced infarct volume by approximately 66% and 28%, respectively, in this experiment.
- Population / setting
- Rat middle cerebral artery occlusion plus HT-22 signaling assays
- Source reviewed
- Indexed citation and abstract reviewed via Europe PMC / PubMed; full methods and risk of bias not comprehensively appraised.
Study limitations
- Animal results do not establish benefit or comparative potency in people.
- Effects are compound-specific and cannot be assigned to all BDNF mimetics.
Reviewed 2026-10-05.
Animal research · 2023
LC-MS/MS determination of GTS-201, a dipeptide mimetic of the brain-derived neurotrophic factor, and neurotransmitter metabolites with application to a pharmacokinetic study in rats.
After intraperitoneal GTS-201 in rats, reported elimination half-lives were about 19.5 minutes in plasma and 87.5 minutes in brain. Relative brain tissue availability was 2.9%; this is not human oral bioavailability.
Study notes and original source
LC-MS/MS determination of GTS-201, a dipeptide mimetic of the brain-derived neurotrophic factor, and neurotransmitter metabolites with application to a pharmacokinetic study in rats.
Markin PA, Moskaleva NE, Lebedeva SA, Kozin SV, Grigorevskikh EM, Kolik LG, Gudasheva TA, Appolonova SA · Journal of pharmaceutical and biomedical analysis
After intraperitoneal GTS-201 in rats, reported elimination half-lives were about 19.5 minutes in plasma and 87.5 minutes in brain. Relative brain tissue availability was 2.9%; this is not human oral bioavailability.
- Population / setting
- Rat pharmacokinetics; plasma and brain LC-MS/MS
- Source reviewed
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
- Preclinical findings do not establish human benefit or safety.
- Abstract only. Full methods and independent replication remain unconfirmed.
Reviewed 2026-10-05.
Experiment described in a patent · 2017
Dipeptide mimetics of NGF and BDNF neurotrophins — US9683014B2
The description enumerates NGF and BDNF analogue series, but the granted US claims specifically identify a Ser-Lys-based dimer rather than every named candidate. GK-1/GK-2 and GSB-104 experiments remain preclinical and include identity or outcome ambiguities.
Study notes and original source
Dipeptide mimetics of NGF and BDNF neurotrophins — US9683014B2
· Primary source linked above
The description enumerates NGF and BDNF analogue series, but the granted US claims specifically identify a Ser-Lys-based dimer rather than every named candidate. GK-1/GK-2 and GSB-104 experiments remain preclinical and include identity or outcome ambiguities.
Results and tables
Reported patent results
Findings described in words
Experimental effects differ by candidate: some dimers were protective or antidepressant-like, while some monomers had unfavorable effects.
Large NGF/BDNF-mimetic patent program with numerous cell and animal comparisons; the granted US claims are narrower than the experimental catalogue.
Population or model Patent chemistry and preclinical examples
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| BDNF-model behavior | GSB-106 and imipramine reduced immobility; GBK-201 and GBK-108 increased it | Different molecules; the unfavorable direction is retained |
| Candidate identity and viability | Some monomeric mimetics reduced neuronal viability; dimeric results were more favorable | Candidate-specific findings, not a class-wide clinical effect |
| Reporting conflict | GSB-104 descriptions and GK-2f structure mapping require reconciliation | No single pooled efficacy percentage inferred from inconsistent examples |
The title and broad description do not mean every experimental candidate is within the granted claims. Cell survival and behavioral proxies do not establish clinical antidepressant or neuroregenerative efficacy.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Patent chemistry and preclinical examples
- Source reviewed
- Selected original-source text checked; full methodological review pending.
Study limitations
- Patent proposals are not established clinical uses.
- Resolve code/structure ambiguities and assay-specific contradictions before interpreting activity.
Reviewed 2026-11-06.
Animal research · 2022
Antidepressant-like Effects of BDNF and NGF Individual Loop Dipeptide Mimetics Depend on the Signal Transmission Patterns Associated with Trk
GSB-106 showed acute antidepressant-like activity; GSB-214 also became active with repeated administration. GTS-201 was inactive in this forced-swim comparison. Different signaling patterns did not yield interchangeable behavioral effects.
Study notes and original source
Antidepressant-like Effects of BDNF and NGF Individual Loop Dipeptide Mimetics Depend on the Signal Transmission Patterns Associated with Trk
· Primary source linked above
GSB-106 showed acute antidepressant-like activity; GSB-214 also became active with repeated administration. GTS-201 was inactive in this forced-swim comparison. Different signaling patterns did not yield interchangeable behavioral effects.
- Population / setting
- Rodent forced-swim tests; comparison with cell-signaling results
- Source reviewed
- Selected original-source text checked; full methodological review pending.
Study limitations
- Behavioral proxies are not a clinical diagnosis or treatment outcome.
- Different schedules and models limit cross-compound comparisons.
Reviewed 2026-10-05.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗